Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536821 · ClinicalTrials.gov registry record
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)
A clinical trial of Parkinson Disease, sponsored by Indiana University.
- Completed
- Registry status
- 81
- Enrollment target
- 10
- Study locations
NCT01536821 is a study of Parkinson Disease that has completed, run by Indiana University. The registered enrollment target is 81 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT01536821, a study of Parkinson Disease, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
- 10
- Study locations
Study Summary
The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an affiliated research facility closest to their home.
Conditions Studied
Study Locations (10)
Florida
- Cleveland Clinic Florida - Weston
Indiana
- Indiana University Medical Center - Indianapolis
Iowa
- University of Iowa Hospitals - Iowa City
Kansas
- Kansas University Medical Center - Kansas City
Maryland
- University of Maryland School of Medicine - Baltimore
Nebraska
- University of Nebraska - Omaha
New York
- Beth Israel Medical Center - New York
Ohio
- Medical University of Ohio - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536821
The ClinicalTrials.gov registry entry for NCT01536821 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01536821 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Florida, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT01536821 about?
NCT01536821 is a clinical study titled "PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)". The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an af...
What is the current status of trial NCT01536821?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2011-05. Estimated completion is 2013-12.
What conditions does trial NCT01536821 study?
This clinical trial studies the following conditions: Parkinson Disease.
Who is sponsoring clinical trial NCT01536821?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01536821 being conducted?
This trial has 10 study locations across Florida, Indiana, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.